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Abstract
Introduction There is little information as to what extent
adverse drug reactions (ADRs) influence patients’ health-
related quality of life (HR-QOL). From a pharmacovigilance
perspective, capturing and making the best use of this
information remains a challenge. The Netherlands Pharma-
covigilance Centre Lareb received about 1800 reports after
the packaging of the drug Thyrax (levothyroxine; Aspen
Pharma Trading Limited, Dublin, Ireland) changed from a
brown glass bottle to a blister package in the Netherlands.
Objective The objective of this study was to explore the
impact of ADRs on HR-QOL in patients who reported a
possible ADR to Lareb in relation to the change in the
packaging of the drug Thyrax. A secondary objective was
to explore factors correlated with change in HR-QOL.
Methods Patients who reported an ADR in relation to the
Thyrax packaging change were included in this study. A
web-based adapted version of the COOP/WONCA ques-
tionnaire was sent to explore the HR-QOL before versus
during the ADR, expressed on a 5-point scale from no
impact (1) to high impact (5). Multivariable linear regres-
sion analysis was used to identify factors correlated with
change in HR-QOL.
Results Overall, 1167 patients returned the questionnaire
(71.2 % response rate). The difference in HR-QOLwas-0.8
for physical, -1.2 for mental, -1.4 for daily activities, -1.3
for social, and -1.3 for overall health status (p\ 0.001 for
each domain). Age, sex, educational level of the patient, and
absence from work due to an ADR were correlated with at
least one domain, while severity of the ADR was found to be
correlated with all domains of HR-QOL.
Conclusion Patients who reported possible ADRs after
the Thyrax packaging change experienced a significant
decrease in HR-QOL. This impact was highest for the
domains ‘daily activities’, ‘overall health status’, and
‘mental health’ and lowest for ‘physical fitness’.
Key Points
In this study population, the ADRs experienced
resulted in a significant decrease in all domains of
health-related quality of life (HR-QOL).
A question about severity may be used by
pharmacovigilance centers to provide a general view
regarding the impact of the ADR on the patient’s
HR-QOL.
1 Introduction
Adverse drug reactions (ADRs) can have a great impact on
a patient’s health-related quality of life (HR-QOL), i.e., the
perception of physical and mental health, the perceived
need for healthcare, and preferences about treatment and
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outcome [1]. Unfortunately, within pharmacovigilance,
e.g., as part of a spontaneous ADR reporting system, sys-
tematic gathering of data on HR-QOL is still uncommon.
Information about the impact of ADRs on a patient’s
HR-QOL can be useful for several purposes. Firstly, it can
be used systematically during the process of signal selec-
tion. The primary aim of pharmacovigilance centers is the
timely detection of unknown ADRs or new information
about known ADRs. This process is also known as ‘signal
detection’. In practice, a signal is a clinically important
event that, if found to be drug related, might have an
impact on patient management or the balance of benefits
and risks [2]. In the process of selecting which potential
signals deserve attention, ADR reports that are classified as
‘serious’ according the Counsel for International Organi-
zations of Medical Sciences (CIOMS) criteria often have
priority over other reports. These criteria include reactions
leading to (prolongation of) hospitalization, life-threaten-
ing events, death, disabling events, congenital abnormali-
ties, and other medically significant reactions [3].
However, non-serious ADRs, e.g., headache, itchiness or
muscle pain, can have a great impact on patient’s HR-
QOL. Systematically gathering this information may help
to identify subgroups of patients with relatively poor HR-
QOL and can in this way be used for signal prioritization.
Secondly, information about the impact of an ADR can
give healthcare professionals insight into how patients feel
and how satisfied they are with the treatment [4]. This can
be illustrated by a study by Baiardini et al. [5] that explored
HR-QOL and well-being in patients with drug-induced
anaphylactic shock. That an anaphylactic shock has impact
on the patient’s HR-QOL is to be expected; however, it was
also found that most patients were worried about taking
any medication after the ADR occurred, even those drugs
that did not cause the allergic reaction. Healthcare pro-
fessionals can use information on the impact of ADRs to
select the most appropriate treatment strategies for the
individual patient and to provide appropriate information
about these ADRs.
Finally, information on the impact of ADRs can be
useful in the process of patients understanding and
accepting ADRs. Lorimer et al. [6] explored patients’
experiences of severe ADRs. Aside from a direct physio-
logical effect of ADRs on a patient, emotions such as
disbelief, anger, fear, frustration, and isolation were com-
monly expressed. Guo et al. [7], who studied ADRs in
tuberculosis patients, showed that ADRs carry a higher
mental well-being burden than a physical one. Van Hunsel
et al. [8] demonstrated that as well altruistic motives, ‘‘I
wanted to be heard’’ is a trigger for patients to report
ADRs. The contact between the patient and their healthcare
providers may also influence how patients experience the
impact of ADRs on their HR-QOL. Awareness of the
possible impact of ADRs on HR-QOL may help patients in
the understanding and accepting of their ADRs and give
them greater perspective on the burden of their disease.
Given the relative lack of literature on how information
about the impact of ADRs on patients’ HR-QOL can be
captured in spontaneous ADR reporting, research is nee-
ded. Since disease type and stage influences a patient’s
perception of the impact of an ADR, we considered it
important to study a relatively homogenous group of
patients. In the period from the end of 2013 until mid 2015,
the Netherlands Pharmacovigilance Centre Lareb received
about 1800 reports after the packaging was changed for the
drug Thyrax (levothyroxine; Aspen Pharma Trading
Limited, Dublin, Ireland) [9]. This is a massive increase
compared to the 167 reports received on levothyroxine in
the period between 2006 and 2010 (an average of two to
three reports per month) [10]. Thyrax was granted mar-
keting authorization in the Netherlands on 6 June 1980 and
is indicated for the treatment of thyroid disorders [11]. At
the end of 2013, the packaging changed from a bottle to a
blister pack at the initiative of the Marketing Authorization
Holder in order to improve protection against various
environmental factors such as light, air, and humidity.
According to the Marketing Authorization Holder, the
formulation of the product had not been changed. Addi-
tional studies indicated that tablets from both the bottle and
the blister meet the quality requirements; however, tablets
from the blister has a slightly better stability [12]. Despite
these findings, Lareb received lots of reports. The most
reported ADRs were symptoms of hyperthyroidism
including palpitations, fatigue, and headache, but symp-
toms of hypothyroidism were also reported as well as
symptoms with no clear explanation. Most of the reports
(85 %) were submitted after media attention about the
Thyrax packaging change in February 2015 (see also
Fig. 1) [13]. Media attention consisted of national televi-
sion coverage and reporting in newspapers [14]. The
reporting pattern for this specific drug after media attention
resembled the reporting pattern in New Zealand after a
formulation change for the drug Eltroxin (thyroxine;
GlaxoSmithKline, Germany) [15, 16].
In the Netherlands, patients have been able to report
ADRs to the pharmacovigilance center since 2003. The
majority of the 1800 reports received on the Thyrax
packaging change were from patients (93 %). All reports
were assessed on a case-by-case by a trained pharma-
covigilance assessor. Feedback was sent to all patients in
response to their reported ADR [17, 18]. On average, the
ADRs were reported 33 (±20) weeks after the start date of
the ADRs.
This study aims to explore the impact of ADRs on the
HR-QOL of patients who reported a suspected ADR to
Lareb in relation to the Thyrax packaging change. We
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were also interested in factors that may influence the
change in HR-QOL, e.g., the outcome of the ADR or its
severity. Therefore, the secondary aim is to explore factors
correlated with the change in HR-QOL during an ADR.
2 Method
2.1 Study Population
The study population consisted of all patients who expe-
rienced an ADR after the change in the packaging of
Thyrax and who reported this to Lareb up until 14 April
2015.
2.2 Measurement of Health-Related Quality of Life
(HR-QOL)
In order to explore the impact of ADRs on the patients’
HR-QOL an adapted version of the COOP/WONCA charts
was used. The COOP/WONCA questionnaire was devel-
oped by the Dartmouth Primary Care Cooperative
Research Network (COOP) and the World Organization of
National Colleges, Academics and Academic Associations
of General Practitioners/Family Practitioners (WONCA).
The Dutch version of COOP/WONCA has been tested in a
community setting and during a hypertension screening.
The validity and psychometric characteristics of the Dutch
COOP/WONCA were found to be acceptable, taking into
account that it concerns a generic instrument [19]. The
COOP/WONCA questionnaire is a self-reported, quick and
simple questionnaire consisting of single-item scales to
explore HR-QOL. The following domains of the COOP/
WONCA were used in this study: physical fitness, social
activities, mental fitness, daily activities, and overall health
status. The items were scored on a 5-level ordinal scale
ranging from 1 (no impact) to 5 (high impact). HR-QOL
was explored for the status at baseline (before the ADR)
and during occurrence of the ADR. Subsequently, a change
score in HR-QOL was calculated.
2.3 Questionnaire Development
A web-based questionnaire was designed and sent by
e-mail using the SurveyMonkey package (SurveyMon-
key, Palo Alto, CA, USA) [20]. On the first question sheet
of the questionnaire we asked about the five domains of
HR-QOL for the situation at baseline. We then asked about
the HR-QOL during the ADR on the subsequent sheet.
Further questions were posted about recovery, the seri-
ousness and severity of the ADR, if the patient was absent
from work due to the ADR, if the patient was able to
discuss the ADRs in a satisfying matter with their health-
care professional, and socio-demographic characteristics.
Completing the questionnaire took approximately
5–10 min. See the Electronic Supplementary Material for a
copy of the questionnaire.
2.4 Sending the Questionnaire
An e-mail invitation to participate in the questionnaire/
study was sent to all eligible patients. A reminder was sent
to all non-responders 1 week after the invitation. Collec-
tion of the responses finished 2 weeks after the first invi-
tation was sent.
The invitation e-mail was uniquely linked to the ques-
tionnaire and the respondent’s e-mail address. Therefore,






















Time lag between start date of the ADR, reporting the ADR 
and completing the questionnaire
Start date ADR Report date of ADR Date of completing the questionnaire
Fig. 1 Time lag between start date of the adverse drug reaction, date of reporting, and completing the questionnaire. ADR adverse drug reaction
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only one response per e-mail address was allowed. Ethics
committee approval was not required as Dutch legislation
does not request this for studies that do not affect the
patient’s integrity [21]. Participant data were sampled and
stored in accordance with privacy regulations.
2.5 Data Analysis
Overall HR-QOL and the HR-QOL change score were
analyzed for each domain using descriptive statistics. A
paired-sample t test was used to analyze statistically sig-
nificant differences in the HR-QOL score before versus
during the ADR. Multivariable linear regression analysis
was carried out to explore factors correlated with changes
in HR-QOL during an ADR. Potential correlating factors
were the following items: recovery (yes/no); seriousness
(yes/no) based on CIOMS criteria [3] and severity of the
ADR (scale from 1 to 10); if the patient was absent from
work due to the ADR (yes/no); if the patient was able to
discuss their ADRs in a satisfying matter with their doctor
and pharmacist (yes/no); age (B20 years, 21–80 years in
six equal categories in steps of 10 years,[80 years); sex;
and educational level (vocational school or lower/higher
professional education or higher). A backward selection
procedure was used with a significance level of\0.05 to
develop the model. To correct for multiple comparisons, a
Bonferroni correction was conducted (corrected a = a/
number of independent significance tests) [22]. It adjusted
for five independent tests, leading to the corrected p value
for significance of\0.01. Data were analyzed using SPSS
Statistics version 22 (IBM Corp., Armonk, NY, USA).
3 Results
3.1 Overall
The questionnaire was sent to 1638 patients and had a
response of 71.2 % (n = 1167). The majority of respon-
dents were female and between 41 and 60 years old
(Table 1). The large majority of respondents had not
recovered from the suspected ADR at the time of reporting.
Only a few reports were categorized as serious. More
respondents reported that they felt that they could discuss
their ADRs better with their physician than with their
pharmacist (Table 2). The average severity of the sus-
pected ADRs as experienced by patients was 6.7 on a scale
from 1 (no severity) to 10 (high severity). The average time
between occurrence of the ADRs and reporting was
8 months (standard deviation [SD] 5 months). The average
time between occurrence of the ADR and completing the
questionnaire was 9 months (SD 5 months) (see also
Fig. 1).
3.2 Quality-of-Life Scores
The overall HR-QOL at baseline ranged from 1.7 to 2.7
(Table 3). In general, patients had the perception that their
HR-QOL was good at baseline. There was a statistically
significant decrease in HR-QOL scores for all domains,















Not reported 35 3.0
Educational level
Vocational school or lower 701 60.1
Higher professional education or higher 455 39.0
Not reported 11 0.9








Absent from work due to the ADR
Yes 569 48.8
No 304 26.0
Not reported/not applicable 294 25.2
Discuss the ADRs in a satisfying matter with their doctor
Yes 809 69.3
No 185 15.9
Not reported/not applicable 173 14.8
Discuss the ADRs in a satisfying matter with their pharmacist
Yes 311 26.6
No 350 30.0
Not reported/not applicable 506 43.4
ADR adverse drug reaction
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with scores between -0.8 and -1.4 (p\ 0.001). The
highest decrease was observed for the domains ‘daily
activities’ followed by ‘social activities’ and ‘overall health
status’.
3.3 Items Correlated with Change in HR-QOL
Multivariable linear regression analysis demonstrated sev-
eral items that showed correlation with changes in HR-
QOL (Table 4). The way the patients experienced the
severity of the ADR (see Fig. 2) was found to be correlated
with all domains of HR-QOL: the higher the severity, the
higher the impact on the patient’s HR-QOL. Sex was found
to be correlated to the domains ‘social activities’ and
‘mental fitness’. For female respondents, the ADRs had a
higher impact on HR-QOL for these domains. For age, it
was found that a higher age resulted in a higher impact of
the ADR on HR-QOL for the domain ‘physical fitness’.
Educational level was found to be correlated with the
‘physical’ domain. An educational level of maximal
vocational school resulted in a higher impact on HR-QOL
than an education of higher professional education/aca-
demic. Analysis further demonstrated that when patients
were absent from work due to the ADR, this had a positive
influence on the domain ‘overall health status’.
4 Discussion
In this study, we used a questionnaire to investigate the
impact of ADRs on the HR-QOL of patients who reported
a possible ADR to Lareb in association with the package
change of the drug Thyrax. Patients are increasingly
systematically involved in the process of drug safety, from
drug development to pharmacovigilance [23], and patients
Table 3 Health-related quality
of life for the domains: physical,
social, mental, daily activities,
and overall health status
Domain QOL Before ADR During ADR Difference in QOL (SE)
Physical fitness 2.3 3.1 -0.8 (1.2)
Social activities 1.7 2.9 -1.3 (1.4)a
Mental fitness 1.8 3.1 -1.2 (1.3)a
Daily activities 1.7 3.1 -1.4 (1.2)
Overall health status 2.7 4.0 -1.3 (1.0)
ADR adverse drug reaction, QOL quality of life, SE standard error
a Difference due to rounding of results
Table 4 Determinants in change of quality-of-life score
Domain QOL Constant Correlated items b 95 % CI R2
Physical 0.006 Severity -0.18 -0.21 to -0.15 0.112
Age 0.06 0.02 to 0.10
Education 0.22 0.10 to 0.35
Social 0.634 Severity -0.29 -0.33 to -0.26 0.188
Sex 0.31 0.08 to 0.54
Mental 0.096 Severity -0.24 -0.27 to -0.20 0.140
Sex 0.37 0.14 to 0.60
Daily activities 0.512 Severity -0.28 -0.32 to -0.25 0.201
Overall health status 0.107 Severity -0.21 -0.24 to -0.19 0.190
Absent from work due to the ADR 0.003 0.002 to 0.004
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Severity of the experienced ADRs
Fig. 2 Severity of the adverse drug reaction on a scale from 1 (no
severity) to 10 (high severity) as experienced by patients. ADR
adverse drug reaction
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are now able to report ADRs directly in a growing number of
countries. It remains a challenge for pharmacovigilance
centers to capture some of the unique features of patient
reports, such as information on HR-QOL, and to make best
use of this information in a spontaneous reporting system.
Since the patient is the one who actually experienced the
ADR,we believe that it is best to ask them about the impact it
has on their HR-QOL. In spontaneous reports, information
on the impact of the ADR on daily life is present in patient
reports more than in healthcare professionals’ reports [24,
25]. This study demonstrated that the reported ADRs had a
significant impact on the patients’ HR-QOL. We found the
highest impact on HR-QOL for the domains ‘daily activi-
ties’, ‘overall health status’, and ‘mental health’, and the
lowest impact for ‘physical fitness’. The decrease in HR-
QOL ranged from -0.8 to -1.4, meaning that, on average,
patients’ HR-QOL dropped by one category on the 5-level
ordinal scale. When interpreting the meaning of this change
in HR-QOL, different perspectives have to be considered.
From the point of view of the patient, ameaningful change in
HR-QOL may be one that results in a considerable increase
in complaints. When the patient is unable to carry out their
daily business, a change of one category on the 5-level
ordinal scale may be a meaningful change in HR-QOL. In
contrast, ameaningful change for the healthcare professional
may be one that indicates a change in the therapeutic treat-
ment or in the prognosis of the disease [26].
Items found to be correlated with change in HR-QOL in
this study were the age, sex and educational level of the
patient, the severity of the ADR, and absence from work
due to the ADR. Little research has been done on the
perceived severity of the ADRs in relation to HR-QOL. In
our study, we measured severity as a subjective represen-
tation of how patients experienced the ADRs scored on a
scale from 1 (no severity) to 10 (high severity) and it was
found to be correlated with all domains in HR-QOL.
Studying HR-QOL in children with epilepsy, Wu et al. [27]
found that patients with several different ADRs experi-
enced lower HR-QOL. Although they did not report the
severity of the ADRs, experiencing several ADRs may
theoretically be related to severity.
It is important to note the difference between severity
and the medical ‘seriousness’. In our study, we used
CIOMS criteria to assess the seriousness of an ADR report
[3]. Other studies used different criteria. For example, Guo
et al. [7] used the term ‘major ADRs’, defined as ADRs
requiring hospital admission, additional treatment, or dis-
continuation of tuberculosis medication which could be
interpreted as ‘serious ADRs’. Using the Short-Form 36
questionnaire to measure HR-QOL, they found that major
ADRs influenced the physical, vitality and mental health
domains. However, because of the disparities in terminol-
ogy, it is difficult to compare the results.
Education level was found to be correlated with ‘phys-
ical fitness’. A higher educational level resulted in a lower
impact on this domain. This result is supported by a study
by Davis et al. [28] exploring the extent to which treat-
ment-related ADRs were associated with cancer-specific
and general quality of life (QOL) [28]. Exploring the
relationship between drug-related problems and HR-QOL
in ambulatory, community-dwelling patients with muscu-
loskeletal disorders, Ernst et al. [29] found that the level of
education was positively related to the change of the
mental component and not to the physical. In their study,
Ernst et al. [29] also explored the impact of ‘positively
addressing’ drug-related problems since this can be an
important step in improving HR-QOL. This determinant
can be compared with ‘‘was the patient able to discuss the
ADRs in a satisfying matter with their healthcare profes-
sional’’ as used in our study. The present study as well as
the study of Ernst et al. [29] found no statistically signifi-
cant effect for this item. Somewhat surprisingly, we found
that ‘‘absence from work due to the ADR’’ had a positive
influence on the domain ‘overall health status’. An expla-
nation could be that patients who are still working despite
the ADR experience much more discomfort than those who
stay at home.
HR-QOL is a psychological construct and thus an
abstract concept that is not directly observable. There is no
gold standard to compare against; the standardized QOL
questionnaires are the best instruments that are available
[30]. There are several general HR-QOL questionnaires
available, but none of them was specifically developed for
the pharmacovigilance setting [31]. We chose the COOP/
WONCA questionnaire because it is a quick and simple,
self-reporting tool that was found to be workable in this
setting. In this questionnaire, each question is a single-item
measurement of an aspect of functional status and it is
advised not to further aggregate the item scores into one
index [19]. HR-QOL was studied using patients who
reported to the pharmacovigilance center. Several previous
studies showed that patients consider the impact of an ADR
on their HR-QOL an important subject and report about it
more often than healthcare professionals [13, 24, 25, 32,
33]. This may partly explain our high response rate of
71.2 %. Furthermore, the response rate may be high due to
the media attention concerning the Thyrax packaging
problem. Finally, in general, previous studies with patient
questionnaires also showed that patients are willing to
provide extra information [8, 17].
A strength of this study is that we included a relatively
homogeneous study population of patients with a (chronic)
thyroid disorder, with the majority of patients being
stable on their medication before occurrence of the ADRs
[13]. Our population reported a relatively high HR-QOL at
baseline, but slightly lower than a population (n = 149,
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mean age 43.4 years, 47 % female) studied by Van Weel
et al. [19] in Emmen, a rural town in the north of the
Netherlands, using the COOP/WONCA questionnaire. HR-
QOL at baseline was the same for the domain ‘social
activities’, but slightly worse in other domains: physical
fitness (2.3 vs. 1.8), mental fitness (1.8 vs. 1.5), daily
activities (1.7 vs. 1.5), and overall health (2.7 vs. 2.4).
More research is needed in other patient groups with
higher/lower HR-QOL at baseline.
Our study has several limitations. We used spontaneous
reports to the Dutch pharmacovigilance center as a basis
of the study. One limitation is the period of time between
onset of the ADR and the time of reporting. If patients did
not remember exactly how they felt before or during the
ADR it may affect the accuracy of their recall regarding
the impact of the ADRs on their HR-QOL. Another
consequence of measuring the impact of ADRs on the
patient’s HR-QOL using data from a pharmacovigilance
center is that only those patients who consider the ADRs
important enough to report them will be included. A
control group of patients who experienced ADRs but did
not report them to the pharmacovigilance center is not
available. Patients who do not report an ADR may
experience a different change in HR-QOL as compared
with those who did report it. Furthermore, we did not
include the type of reported ADR in our analysis as a
possible determinant. Since most patients reported several
ADRs (average of four ADRs per report [9]), this was not
considered feasible.
4.1 Practical Implications
The perceived severity of the ADR was found to be a
determinant for all domains of HR-QOL. The strong rela-
tionship between severity and impact is a valuable finding
from the perspective of a pharmacovigilance center. Add-
ing HR-QOL questions to the regular ADR reporting form
carries the risk that the form becomes too time-consuming
to complete. If one question about severity gives a reflec-
tion of the patient’s perception of the impact of the ADRs
on their HR-QOL, this question could be used on the
reporting form. This aspect should be further investigated.
Information regarding severity can be used in the process
of signal selection and prioritization. When an ADR has a
high severity in a significant share of the reports, this may
be a trigger to undertake action. As already highlighted,
information about the impact of ADRs can also be valuable
for other stakeholders in pharmacovigilance, for example
healthcare professionals and patients. Follow-up studies are
needed to explore in which ways this information can best
be provided and used for these stakeholders.
In order to avoid one of the main limitations of our
study, namely the recall bias, follow-up studies could focus
on a prospective cohort approach, for instance the Lareb
Intensive Monitoring system. In this system, patients
receive a questionnaire directly after the start of a new
drug, followed by some follow-up questionnaires [34].
Using this method, you are able to ask patients about their
HR-QOL directly after the event occurred.
5 Conclusion
Patients who reported possible ADRs after the Thyrax
packaging change experienced a significant decrease in
HR-QOL. This impact on HR-QOL was the highest for the
domains ‘daily activities’, ‘overall health status’, and
‘mental health’ and the lowest for ‘physical fitness’. Only
the severity of the ADR was found to be correlated with all
domains of HR-QOL.
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